trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Propranolol therapy in infants and children can be associated with hypoglycemia, particularly during fasting.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
5 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Propranolol therapy in infants and children can be associated with hypoglycemia, particularly during fasting?

Yes. Propranolol therapy in infants and children is well-documented to carry a risk of hypoglycemia, particularly in the context of fasting or irregular feeding schedules, requiring careful clinical monitoring and caregiver education.

Verdict: SUPPORTED · 5 sources for, 0 against · Last checked

The analysis

The retrieved literature consistently confirms that propranolol, a non-selective beta-blocker used in pediatric populations (such as for infantile hemangiomas), is associated with hypoglycemia, especially when children experience fasting or skipped meals. Multiple clinical reviews and safety analyses identify hypoglycemia as a primary adverse risk, thus supporting the claim.

Evidence for · 5
Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β-Blockers to PI3K/AKT/mTOR Inhibitors.
2026
Get citation
H, A. & M, D. (2026). Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β-Blockers to PI3K/AKT/mTOR Inhibitors.. doi.org. https://doi.org/10.1111/jcmm.71103

See more details
More for · 4
Clinical Pharmacology of Propranolol in Infants and Children
2021
Get citation
Pacifici, G. M. (2021). Clinical Pharmacology of Propranolol in Infants and Children. doi.org. https://doi.org/10.31579/2768-0487/037

Orphan drug propranolol for infantile hemangioma: ten-year real-world safety data from the FAERS database.
2026
Get citation
X, L., X, Z., C, Y., & A, C. (2026). Orphan drug propranolol for infantile hemangioma: ten-year real-world safety data from the FAERS database.. doi.org. https://doi.org/10.1186/s13023-026-04331-4

Severe Hypoglycemia-Induced Seizure in a Four-Year-Old Following Initiation of Nadolol for Supraventricular Tachycardia.
2026
Get citation
ZM, A. M., AM, H. A., R, A. A., N, M., & A, A. (2026). Severe Hypoglycemia-Induced Seizure in a Four-Year-Old Following Initiation of Nadolol for Supraventricular Tachycardia.. doi.org. https://doi.org/10.7759/cureus.103387

Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives.
2026
Get citation
B, N. & C, O. (2026). Therapies for Infantile Haemangiomas: Current Practice and Evolving Perspectives.. doi.org. https://doi.org/10.1007/s13555-026-01784-0

What does the evidence say?

The retrieved literature consistently confirms that propranolol, a non-selective beta-blocker used in pediatric populations (such as for infantile hemangiomas), is associated with hypoglycemia, especially when children experience fasting or skipped meals. Multiple clinical reviews and safety analyses identify hypoglycemia as a primary adverse risk, thus supporting the claim.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work